Gilead Licenses Obeldesivir to Three Generic Makers
Royalty-free agreements cover 127 mostly low- and lower-middle-income countries as Ebola Bundibugyo outbreak tops 10,000 cases across Africa.
Updated on Nov. 17, 2026 in Diseases — General

Live Poll
Do you trust drug companies to share new medicines fairly with poorer countries?
Gilead Sciences has signed royalty-free voluntary licensing agreements for its investigational antiviral obeldesivir with Dr Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories. The agreements cover 127 primarily low- and lower-middle-income countries, including all African countries that have reported cases during the ongoing Ebola outbreak.
Why it matters
There is no approved treatment or vaccine for the Bundibugyo virus, and the outbreak has exceeded 10,000 cases across Africa. The licenses prepare for future access while clinical research on obeldesivir is still ongoing.
The licenses cover 127 countries through three manufacturers, while the outbreak has exceeded 10,000 cases across Africa. Whether obeldesivir will prove effective against Bundibugyo virus remains unknown until the Phase 3 trial reports results.
The players
Gilead Sciences
Gilead Sciences is a California-based biopharmaceutical company that develops antiviral medicines, including obeldesivir.
Dr Reddy's Laboratories
Dr Reddy's Laboratories is an Indian multinational pharmaceutical company that manufactures generic medicines for global markets.
Eva Pharma
Eva Pharma is an Egyptian pharmaceutical company that produces generic medicines across the Middle East and Africa.
Ferozsons Laboratories
Ferozsons Laboratories is a Pakistani pharmaceutical manufacturer that produces generic drugs for domestic and export markets.
The details
Gilead will support Dr Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories in manufacturing readiness, technology transfer and supply planning. The Alliance for International Medical Action is overseeing coordination of the EBO-PEP global trial with national and international partners.
Timeline
August 2026: The World Health Organization termed the outbreak the deadliest Ebola outbreak in the history of the Democratic Republic of Congo, with 2,325 deaths.
November 17, 2026: Gilead announced the licensing agreements.
Big Picture
The current outbreak's 2,325 deaths surpass the 2018-2020 Congo outbreak's toll of 2,299, marking a new high for the country. Licensing obeldesivir for generic production follows the pattern of pandemic-era access efforts, though no approved therapy yet exists for Bundibugyo virus.
The licenses aim to enable future access to obeldesivir in countries hit hardest by Ebola once clinical trials and regulatory approval are complete. Until then, no approved treatment or vaccine exists for Bundibugyo virus disease, so the drug's availability depends on trial outcomes.
The takeaway
Royalty-free licensing can speed generic access to a promising antiviral before its efficacy is proven, but patients in affected regions should watch for Phase 3 trial results to know whether the drug will be available.
Further reading
For broader context on how infectious outbreaks are tracked and treated, see Diseases — General.
Live Poll
Do you trust drug companies to share new medicines fairly with poorer countries?



